Alivas

Alivas is a pioneering medical company focused on developing new therapeutic devices for treating refractory constipation, established in 2017. The company's slogan underscores its commitment to international collaboration and innovation in addressing this critical health issue. It is a collaborative venture between Stanford University and the University of Tokyo, operating under the Japan Biodesign program. With its headquarters located in Hongo, Tokyo, Japan, Alivas operates within the Biotechnology, Health and Wellness, and Medical Devices sectors. The company recently secured a significant ¥190.00M Series A investment on 20 July 2020, with DBJ Capital and MedVenture Partners serving as the key investors. This investment is poised to fuel Alivas' innovative efforts in developing advanced therapeutic solutions, marking a significant milestone in the company's growth and promising future prospects.